{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CAREMM-002","nct_id":"NCT05979363","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=caremm-002-nct05979363. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CAREMM-002","arms":[{"description":"VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.\n\nAutologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\\^6 anti-BCMA CAR+T cells/kg.\n\nParticipants will receive VRD-based induction, BCMA CAR-T infusion, VR consolidation, VR maintenance.","label":"VRD-based Regimen Combined With BCMA CART","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-07-01","type":"ESTIMATED"},"conditions":["Plasma Cell Leukemia"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"anti-BCMA CAR-T","otherNames":[],"type":"BIOLOGICAL"},{"name":"VRD-based regimen","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-03","lead_sponsor":"Institute of Hematology & Blood Diseases Hospital, China","official_title":"Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and Tolerability","timeFrame":"Up to 2 year"},{"measure":"MRD-negative rate","timeFrame":"within 1 week after consolidation treatment"}],"references":[],"start_date":{"date":"2023-08-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia","url":"https://clinicaltrials.gov/study/NCT05979363"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/caremm-002-nct05979363"}